U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07104162) titled 'A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment' on July 29.

Brief Summary: A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam (S-649228) in Participants with Renal Impairment

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Bacterial Infections

Intervention: DRUG: Cefiderocol/Xeruborbactam

A fixed dose combination of intravenous cefiderocol and intravenous xeruborbactam

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Qpex Biopharma, Inc.

Disclaimer: Cu...